Too Much Cash? In Biotech?
Maxygen Buying Back Stock; Analysts Say No Trend Here
By Trista Morrison
Monday, November 16, 2009
Maxygen Inc. on Friday became the latest member of a very small biotech cadre that is returning cash to shareholders. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.